HFB200603 IND Filing

HFB200603 IND filing is anticipated in the second half of 2022.

Overview of HFB200603

• Proportional dose near or proportional dose in dose with exposure in increase.
• Necropsy at changes macroscopic no observation detectable ADA no clinical with manner temperature, a in suppression.
• TCR 200603 HFB of mediated-HVEM antibody parental reverse to the ability is 3-6 their HFB.

Functional Characteristics

• Based antibody blocking selected were BTLA-anti blockers benchmark a is Ab Functional.
• CDRs Bmk. Cells diverse with reporter luc- binders NFAT. BTLA BTLA.
• Jurkat potent immune profiling platform - single Drug Intelligent Science (DIS HiFiBiO’s).

Toxicokinetic Analysis

• Body collected weight, body consumption, food in abnormalities No. 200603 HF of analysis.
• Screening for immunized cell single based- Splenocytes droplet ™ CelliGO to subjected and enriched.
• Protein fusion favorable developability and pharmacokinetic profiles were group was per plasma which after cynomolgus infusion.

Evaluations

• Experimental design 200603 HFB of obvious (high) mg/kg Scheme
• NHPs (medium) 200603 mg/kg HFB of mg/kg evaluation 1h of 336 dose toxicological single.
• Points with Exploratory.5 administered.

Conclusions

• Favorable acute toxicity profile in cynomolgus monkeys in primary tumor culture and pro-inflammatory cytokine production γ 1 in inducing IFN.
• PD-Exhibit single agent effect and combinatorial effect with anti binding blocking activity.
• Potent ligand and digit nanomolar affinity BTLA with single cyno binding specifically to human/mAb BTLA.

References and Results

• Highlight of HFB200603: 100mg/kg, Male HFB200603, 10mg/kg, Female.
• Diverse CDRs HVEM interaction and selected clinical BTLA antibodies capable of blocking BTLA.
• HFB200603 was characterized for binding affinity, cross-reaction with anti melanoma, NSCLC, and HCC.

Results Summary

Presenting Qian Zhang, Bingqing Shen, Manan Shah, Mingjie Chen, Sharon Li, Ling Dong, Francisco Adrian, Liang Schweizer, Juying Li.